Phase 2 RCT: Efficacy and safety of mavrilimumab in giant cell arteritis.

Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial – Annals of Rheumatic Diseases

Commentary on Twitter

New phase II trial data ? for #giantcellarteriitis: Mavrilimumab, an anti-GM-CSF antibody, showed:
✅ longer time to flare
✅ higher rate of sustained remission
❎ similar rate of adverse events compared to placebohttps://t.co/2MDLch2Zmg pic.twitter.com/Rl1AgamQKG

— ARD & RMD Open (@ARD_BMJ) March 10, 2022